InvestSMART

Amplia Therapeutics Limited (ASX:ATX)

ALERT: Price-sensitive ASX Announcement for ATX
Current share price for ATX : $0.150 0.02 (15.38%)+
Announcement
Release
29 Jul 2026 8:29AM
Price at Release
$0.130
Full Release
download
Summary
Amplia Therapeutics Limited reported significant progress in its cancer treatment programs, notably presenting mature data from the ACCENT trial for narmafotinib at the AACR meeting, which demonstrated improved safety and efficacy in metastatic pancreatic cancer. The company has initiated a Phase 2b study involving narmafotinib with chemotherapy agents, and partnered with ANZGOG to launch the PRROSE trial for ovarian cancer. The company saw changes in leadership with Ms Jane Bell AM becoming Chair, and has expanded its intellectual property with a new patent application for FAK inhibitors. Financially, the quarter ended with A$24 million in cash, despite a net operating cash outflow of A$3.9 million. No proceeds from financing activities were recorded during the quarter.
Key Points
  • Mature ACCENT trial data presented at AACR meeting showing positive results for narmafotinib in pancreatic cancer.
  • Initiation of Phase 2b study on narmafotinib in combination with gemcitabine and Abraxane® for pancreatic cancer.
  • Partnership with ANZGOG for PRROSE trial in ovarian cancer.
  • Board leadership transition with Ms Jane Bell AM appointed Chair.
  • New patent application filed for novel FAK inhibitors.
  • Quarter ended with a cash position of A$24 million.
  • Net operating cash outflows of A$3.9 million for the quarter.
  • No proceeds from financing activities in the quarter.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.